drugset / Trial / NCT04767581
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those receiving placebo.
Timeline
- Start
- 2021-03-08
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tenapanor | Small molecule | 5 mg | Oral |
| Comparator | Tenapanor | Small molecule | 10 mg | Oral |
| Comparator | Tenapanor | Small molecule | 20 mg | Oral |
| Comparator | Tenapanor | Small molecule | 30 mg | Oral |